Last reviewed · How we verify
Poly IC
Poly IC is a synthetic double-stranded RNA analog that activates innate immune responses through toll-like receptor 3 (TLR3) signaling.
Poly IC is a synthetic double-stranded RNA analog that activates innate immune responses through toll-like receptor 3 (TLR3) signaling. Used for Cancer immunotherapy (various malignancies), Viral infections.
At a glance
| Generic name | Poly IC |
|---|---|
| Also known as | Polyinosinic-polycytidylic acid injection |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Drug class | TLR3 agonist / Immunostimulant |
| Target | TLR3 (Toll-like receptor 3) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Poly IC (polyinosinic-polycytidylic acid) mimics viral double-stranded RNA and binds to TLR3 on immune cells, triggering interferon production and activation of natural killer cells and cytotoxic T lymphocytes. This enhances antiviral and antitumor immune responses through pattern recognition receptor activation.
Approved indications
- Cancer immunotherapy (various malignancies)
- Viral infections
Common side effects
- Fever
- Fatigue
- Myalgia
- Flu-like symptoms
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (PHASE1)
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (PHASE1)
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (PHASE1)
- A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma (PHASE1)
- Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PHASE1)
- Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) (PHASE2)
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: